A standard-driven approach for electronic submission to pharmaceutical regulatory authorities

2018 ◽  
Vol 79 ◽  
pp. 60-70 ◽  
Author(s):  
Ching-Heng Lin ◽  
Hsin-I Chou ◽  
Ueng-Cheng Yang
2018 ◽  
Vol 1 (2) ◽  
pp. 7-10
Author(s):  
Jitendra Kumar Badjatya ◽  
Ramesh Bodla

The urgent requirement to rationalize and harmonize regulation was impelled by instance of rising cost of Healthcare, Research and Development and need to meet the public requirement to approach for the safe and efficacioustreatments to patient in need. ICH committee has given priority to harmonize the format of reporting data for quality,safety and Efficacy in the application dossier.ICH also provides different Guidelines under the topic Quality, Safety, Efficacy and Multidisciplinary to control thequality safety and efficacy of Pharmaceutical and Biotechnological products.For the dossier application part CTD provides harmonized format for product application. Earlier all the submissionssent to regulatory authorities in CTD, Paper format but it was a tedious job requiring lot of Time to review,documentation and paper work.Due to the advancement in Information technology, regulatory authorities from regulated countries throughout theglobe started to accept data in electronic format either in eCTD (Electronic common technical document)/ NeeS (NoneCTD electronic submission).The eCTD was developed subsequently by the ICH M2 Expert working group and allows for the electronicsubmission of the CTD from the applicant to regulator and provides harmonized technical solution for CTDelectronically. Many regulatory authorities completely eliminated the Paper submission and made eCTD mandatory.This is the centralized approach, saves time, cost, facilitate review process and greater transparency can be achievedvia central processing of submissions.Harmonization can also be seen in IPR stream by treaties and conventions. These international treaties andconventions contribute to the process of harmonization of patent laws.


2017 ◽  
Author(s):  
Carrie A. Bulger ◽  
Mark E. Hoffman ◽  
Sara J. McKersie ◽  
Larissa K. Barber ◽  
Jade Jenkins ◽  
...  

Author(s):  
Paramjeet Malik ◽  
Neelam Pawar ◽  
Kavita Bahmani

: Safety, efficacy and quality of a therapeutic product is the major concern for the pharmaceutical companies. FDA and PMDA are the main regulatory authorities in USA & JAPAN respectively that ensures the maintenance of these required parameters by forming standard guidelines and process for drug approval. These regulatory authorities’ reviews each step of a pharmaceutical drug product from its discovery phase to marketed product. Dossier plays an important role during the approval process of a drug product, as it allows both applicant and review team members to evaluate the data in an effective manner. A dossier consists of five modules containing informative data of various stages of a drug product but in a brief pattern with folders and subfolders. In the present paper, the authors focus on in-depth review of approval process for new and generic drugs in USA and Japan.


Sign in / Sign up

Export Citation Format

Share Document